ASCO 2023 | Role of BCMA-targeting ADCs in the management of myeloma
Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the use of belantamab mafodotin, a BCMA-targeting antibody-drug conjugate (ADC), in heavily pre-treated patients with relapsed/refractory (R/R) multiple myeloma. This agent was approved by the U.S FDA and withdrawn based on results from the DREAMM-3 trial (NCT04162210). Dr Lee highlights the potential of BCMA-targeting antibody-drug conjugates in multiple myeloma, touching on the importance of determining the optimal dosing schedule for belantamab mafodotin. Upcoming trial readouts from DREAMM-8 (NCT03715478) and DREAMM-9 (NCT04091126) are expected to shed more light on the role of belantamab mafodotin in patients with multiple myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
